Wall Street analysts expect Kezar Life Sciences Inc (NASDAQ:KZR) to report earnings per share of ($0.44) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Kezar Life Sciences’ earnings. The highest EPS estimate is ($0.35) and the lowest is ($0.63). The business is scheduled to issue its next earnings results on Thursday, February 14th.
On average, analysts expect that Kezar Life Sciences will report full year earnings of ($2.22) per share for the current year, with EPS estimates ranging from ($2.38) to ($1.90). For the next financial year, analysts anticipate that the business will report earnings of ($2.15) per share, with EPS estimates ranging from ($2.84) to ($1.62). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings data on Thursday, November 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.18.
Several analysts have issued reports on KZR shares. Zacks Investment Research downgraded shares of Kezar Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 24th. ValuEngine downgraded shares of Kezar Life Sciences from a “buy” rating to a “hold” rating in a report on Thursday, December 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $27.33.
Several hedge funds have recently made changes to their positions in the company. FMR LLC acquired a new stake in shares of Kezar Life Sciences during the second quarter worth $25,995,000. BlackRock Inc. boosted its position in shares of Kezar Life Sciences by 2,314.5% during the 3rd quarter. BlackRock Inc. now owns 241,446 shares of the company’s stock valued at $5,169,000 after purchasing an additional 231,446 shares in the last quarter. Millennium Management LLC bought a new position in shares of Kezar Life Sciences during the 2nd quarter valued at about $1,300,000. EcoR1 Capital LLC boosted its position in shares of Kezar Life Sciences by 1.3% during the 3rd quarter. EcoR1 Capital LLC now owns 1,288,198 shares of the company’s stock valued at $27,580,000 after purchasing an additional 16,000 shares in the last quarter. Finally, Prosight Management LP boosted its position in shares of Kezar Life Sciences by 25.5% during the 3rd quarter. Prosight Management LP now owns 52,331 shares of the company’s stock valued at $1,120,000 after purchasing an additional 10,640 shares in the last quarter. Institutional investors and hedge funds own 47.40% of the company’s stock.
Shares of KZR opened at $23.51 on Friday. Kezar Life Sciences has a 1 year low of $14.77 and a 1 year high of $36.33.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Featured Story: What is a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.